Similar Items: Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience
- From clinical trial to clinical experience: Lecanemab therapy in a real‐world case series
- Real‐world use of lecanemab: patient pathway findings from a US multicenter study
- Investigating the amyloid–tau–neurodegeneration framework in Alzheimer's disease using semi‐supervised multimodal imaging data fusion
- Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging
- Clinical and MRI features associated with amyloid positivity in secondary screening for anti–amyloid‐β therapy
- Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment